MyoPax develops proprietary regenerative stem cell therapies utilizing patented methods for isolating and cultivating primary human satellite cells, alongside CRISPR/Cas gene-editing technologies for precise gene repair. The company targets muscle function loss due to disorders such as muscular dystrophies and trauma, aiming to restore muscle health and improve patients' quality of life.
Funding
$10.2M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Many patients with muscle disorders currently receive only palliative care, facing a continuously decreasing quality of life and premature death due to conditions like congenital malformation, trauma, hereditary muscular dystrophies, acute conditions, or aging. Major loss of muscle function can prevent patients from working and performing basic life activities.
Solution
MyoPax is developing regenerative stem cell and gene therapies aimed at restoring muscle function in patients with muscle disorders. The company's approach involves using patented methods for isolating and cultivating primary human satellite cells (PHSats), combined with CRISPR/Cas gene-editing technologies for precise gene repair. MyoPax is also engineering hypo-immune PHSats-analogs from induced pluripotent stem cells for allogeneic therapy. These technologies are being developed to address both local muscle defects and muscle-wasting disorders.
Target Audience
The primary target audience includes patients suffering from muscle function loss due to congenital malformation, trauma, hereditary muscular dystrophies, acute and/or critical conditions including cancer, or aging.
Features
- Patented method for isolating and cultivating PHSats, enabling the production of high-purity muscle stem cell populations.
- Engineering of hypo-immune PHSats-analogs from induced pluripotent stem cells for allogeneic therapy.
- Mutation-specific gene-editing toolkits based on CRISPR/Cas technology for precise and efficient repair of single-point mutations in genes encoding therapeutically relevant muscle proteins.
- mRNA-delivered gene repair for long-term healthy muscle regeneration using repaired patient stem cells.